Circulating levels of sPD‐L2 together with an altered CD4/CD8 ratio could be used as indicative of the persistence of lung lesions post‐COVID‐19 in COVID‐ILD patients, although sPD‐L1 could be helpful to improve the diagnosis during acute COVID‐19. This evidence concerns the gene CD8A and COVID-19.